TY - JOUR T1 - Nebulised hypertonic saline does not reduce hospital length of stay in acute bronchiolitis JF - Evidence Based Medicine JO - Evid Based Med SP - 106 LP - 106 DO - 10.1136/ebmed-2015-110168 VL - 20 IS - 3 AU - Todd A Florin Y1 - 2015/06/01 UR - http://ebm.bmj.com/content/20/3/106.abstract N2 - Commentary on: Everard ML, Hind D, Ugonna K, et al. SABRE: a multicenter randomized control trial of nebulised hypertonic saline in infants hospitalised with acute bronchiolitis. Thorax 2014;69:1105–12OpenUrlAbstract/FREE Full Text.Acute bronchiolitis is the most frequent lower respiratory infection in infancy, yet no therapy has shown consistent benefit.1 Although initially promising, there is now conflicting evidence regarding the efficacy of nebulised 3% hypertonic saline (HS). In 2013, a Cochrane meta-analysis concluded that HS may significantly reduce the hospital length of stay among infants hospitalised with mild-to-moderate bronchiolitis and also improve clinical severity scores.2 Other studies suggest that HS has no effect on length of stay.3 ,4This study was a multicentre, parallel-group, open-label randomised trial comparing 4 mL of nebulised HS administered every 6 h to standard supportive care in infants aged <1 year hospitalised at 1 of 10 hospitals in the … ER -